FDA Approves Omisirge as First Cell Therapy for Severe Aplastic Anemia
核心洞察
The FDA has approved Omisirge (Omidubicel-onlv) as the first cell therapy treatment for severe aplastic anemia (搜索), marking a significant milestone for patients with this rare blood disorder.
Clinical trial results showed 86% of patients achieved early and sustained neutrophil recovery at 100 days with a median recovery time of just 11 days.
The therapy demonstrated exceptional safety with no cases of severe acute or chronic graft-versus-host disease and achieved a 92% disease-free and overall survival rate.
The U.S. Food and Drug Administration has approved Omisirge (Omidubicel-onlv) as the first cell therapy for treating severe aplastic anemia (搜索) (SAA), offering a new treatment option for patients with this rare, life-threatening blood disorder. The approval, announced by Ayrmid Ltd (搜索)., parent company of Gamida Cell Inc (搜索)., represents a supplementary FDA approval for Omisirge, which was initially approved for hematological malignancies in 2023.
Clinical Trial Results Demonstrate Rapid Recovery
The FDA approval is based on an ongoing open-label, single-center study led by Dr. Richard Childs of the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH). The trial demonstrated remarkable efficacy outcomes that exceeded expectations for high-risk aplastic anemia patients.
Key clinical results include a median time to neutrophil recovery of just 11 days, with 86% of patients achieving early and sustained neutrophil recovery at 100 days. The therapy also showed strong performance in achieving transfusion independence, with 86% of patients no longer requiring red blood cell transfusions.
"Patients in the study with aplastic anemia were high risk, but had significantly better than expected outcomes and demonstrated remarkably fast and high rates of neutrophil engraftment," said Dr. Richard Childs. "This was achieved with low rates of mild acute GVHD and no chronic GVHD meaning the patients achieved a rapid return to a normal life."
Exceptional Safety Profile
The study revealed an outstanding safety profile with no cases of BMT-CTN severe acute graft-versus-host disease (GVHD) or chronic GVHD observed. This represents a significant advantage over traditional stem cell transplantation approaches, which often carry substantial risks of these serious complications.
The therapy achieved a 92% disease-free and overall survival rate, while immune recovery post-transplant was rapid. These results suggest that Omisirge may offer both superior efficacy and safety compared to existing treatment options.
Addressing Critical Unmet Medical Need
Severe aplastic anemia (搜索) is a rare, life-threatening hematologic disorder in which the bone marrow fails to produce sufficient blood cells. While stem cell transplantation offers a potential cure, many patients lack a matched sibling donor, creating a significant treatment gap.
"The approval of Omisirge is a significant step forward in the treatment options available for patients with a high unmet medical need," noted Dr. Childs.
Dr. Joe Wiley, Ayrmid Chairman and Chief Executive Officer, emphasized the transformative potential of this approval: "Omisirge is a new and novel transplant option for the many SAA patients who do not have a matched related donor. This approval is potentially transformative for patients living with SAA, given the rapid and sustained recovery of blood counts observed."
Manufacturing Expansion Plans
To meet anticipated demand from SAA patients, Ayrmid has established a strategic partnership with RoslinCT (搜索) for U.S. production of Omisirge. The technology transfer and commercial manufacturing will take place in RoslinCT's state-of-the-art, purpose-built cell therapy CGMP manufacturing facility in Hopkinton, Massachusetts, beginning in 2027.
This manufacturing expansion represents a significant investment in ensuring patient access to this breakthrough therapy and demonstrates the company's commitment to meeting the needs of the SAA patient population.